ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALK Alkemy Capital Investments Plc

92.50
-5.00 (-5.13%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Alkemy Capital Investments Plc LSE:ALK London Ordinary Share GB00BMD6C023 ORD GBP0.02
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -5.13% 92.50 90.00 95.00 97.50 92.50 97.50 54,098 09:45:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices-holdng Companies,nec 0 -2.65M -0.3239 -2.86 7.55M

0OIR Annual General Meeting In Alk-Abelló A/S Held On 16 March 2022

16/03/2022 4:58pm

UK Regulatory


 
TIDMALK TIDMB 
 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 16 March 2022.

The Annual General Meeting transacted the following business:

   -- Adoption of the annual report 2021 and discharge of the Board of 
      Directors and Board of Management 
 
   -- No declaration of ordinary dividend in accordance with the approved 
      annual report for 2021 
 
   -- Adoption of the remuneration report for 2021 
 
   -- Adoption of the remuneration to the Board of Directors for the present 
      year 
 
   -- Re-election of Anders Hedegaard as the Chairman of the Board of Directors 
 
   -- Re-election of Lene Skole as the Vice Chairman of the Board of Directors 
 
   -- Re-election of Gitte Aabo, Lars Holmqvist, Bertil Lindmark and Jakob Riis 
      as well as new election of Alan Main to the Board of Directors 
 
   -- Re-appointment of PwC Statsautoriseret Revisionspartnerselskab as the 
      company's auditor 
 
   -- Adoption of the following proposals from the Board of Directors: 

(a) Renewal of the Board's powers to increase the share capital (article 4a of the Articles of Association)

(b) Amendment of the denomination of shares

(c) Amendment of article 6.4 of the Articles of Association

(d) Authorisation to the chairman of the meeting

ALK-Abelló A/S

For further information please contact:

Anders Hedegaard, Chairman, tel. +45 4574 7576

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

   -- FM_05_22UK_16032022 
      https://ml-eu.globenewswire.com/Resource/Download/19ec0e6e-5701-4b3d-95be-8de086a1b806 
 
 
 

(END) Dow Jones Newswires

March 16, 2022 12:58 ET (16:58 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Alkemy Capital Investments Chart

1 Year Alkemy Capital Investments Chart

1 Month Alkemy Capital Investments Chart

1 Month Alkemy Capital Investments Chart

Your Recent History

Delayed Upgrade Clock